Akero Therapeutics Stock Options
| AKRO Stock | USD 25.14 1.13 4.71% |
Akero Therapeutics' latest option contracts expiring on March 21st 2025 are carrying combined implied volatility of 2.4 with a put-to-call open interest ratio of 0.01 over 21 outstanding agreements suggesting investors are buying way more calls than puts on contracts expiring on March 21st 2025. The total put volume is at 305, with calls trading at the volume of 370. This yields a 0.82 put-to-call volume ratio.
Open Interest Against March 21st 2025 Option Contracts
2025-03-21
The chart above shows Akero Therapeutics' distribution of open interest by maturity on contracts that have not yet been settled. The area between the two highest points is the projection of the price at expiration. Akero Therapeutics' open interest chart also provides vital information regarding the liquidity of an option. If there is no open interest for Akero Therapeutics' option, there is no secondary market available for investors to trade.
In The Money vs. Out of Money Option Contracts on Akero Therapeutics
Analyzing Akero Therapeutics' in-the-money options over time can help investors to take a profitable long position in Akero Therapeutics regardless of its overall volatility. This is especially true when Akero Therapeutics' options are deep in the money. These options can be identified using deltas that are over 0.75. Deep in-the-money Akero Therapeutics' options could be used as guardians of the underlying stock as they move almost dollar for dollar with Akero Therapeutics' stock while costing only a fraction of its price.
Please note that buying 'in-the-money' options on Akero Therapeutics lessens the impact of time decay, as they carry both intrinsic and time value. So, even if Akero Therapeutics' value remains static through the expiration date, the investor can sell to close an 'in-the-money' option to avoid a potential loss. However, in-the-money Akero Therapeutics contracts are usually more expensive to enter than their out-of-the-money counterparts. So keep in mind that while the payoffs on an in-the-money trade can be high, the investors could ultimately experience a more consequential loss if Akero Stock moves the wrong way.
Akero Therapeutics In The Money Call Balance
When Akero Therapeutics' strike price is surpassing the current stock price, the option contract against Akero Therapeutics stock is said to be in the money. When it comes to buying Akero Therapeutics' options that are 'In the Money' or 'Out of the Money', the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
While 'out-of-the-money' option contracts written on Akero Therapeutics are typically viewed as the more aggressive, there are potential upsides to purchasing these types of options contracts. For one, the cost to buy an 'Out of the Money' option is lower than the cost to buy an 'In the Money' option. This cost-benefit is due to the fact that at the time of the purchase, 'Out of the Money' contracts have no intrinsic value. So, while the potential for a 100% loss is more significant, the cost and risk to enter the trade are lower.
Akero Current Options Market Mood
Akero Therapeutics' open interest and total value indicators provide investors with the necessary information to digest the overall options buildup for its expiring contracts. In addition, it helps Akero Stock's traders understand whether a recent fall or rise in the market is unreasonable and if the time has come to take contrarian positions. These ratios are calculated based on options trading volumes and current open interest.
Put-to-Call Open Interest
Put-to-Call Volume
Unfortunately, most Akero Therapeutics' options investors are not very successful. Akero Therapeutics' option open interest and volume spread between outstanding puts and calls are regarded by many investors as reliable indicators of the overall future market direction.
Rule 16 of the current Akero contract
Base on the Rule 16, the options market is currently suggesting that Akero Therapeutics will have an average daily up or down price movement of about 0.15% per day over the life of the 2025-03-21 option contract. With Akero Therapeutics trading at USD 25.14, that is roughly USD 0.0377. If you think that the market is fully incorporating Akero Therapeutics' daily price movement you should consider buying Akero Therapeutics options at the current volatility level of 2.4%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
Akero |
Purchasing Akero Therapeutics options can give investors a meaningful hedge against losses and, therefore, could be used conservatively to decrease the volatility of your portfolio. However, many options could also amount to little more than gambling, significantly enhancing your overall portfolio risk. One simple example of these aggressive strategies is the sale of "uncovered" Akero calls. Remember, the seller must deliver Akero Therapeutics stock to the call owner when a call is exercised.
Akero Therapeutics Option Chain
When Akero Therapeutics' strike price is surpassing the current stock price, the option contract against Akero Therapeutics stock is said to be in the money. When it comes to buying options that are ITM or OTM, the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
Akero Therapeutics' option chain is a display of a range of information that helps investors for ways to trade options on Akero. In general, an option chain provides a helpful tool for investors to see all available option contracts, both puts, and calls, for Akero. It also shows strike prices and maturity days for a Akero Therapeutics against a given expiration period. The table below combines all the option information in the form of a chain but before you use it, remember that it entails significant risk and it is not for everyone. | Open Int | Strike Price | Current Spread | Last Price | |||
Call | AKRO250321C00017500 | 0 | 17.5 | 9.6 - 14.5 | 9.6 | In |
Call | AKRO250321C00020000 | 19 | 20.0 | 8.9 - 13.5 | 10.6 | In |
Call | AKRO250321C00022500 | 207 | 22.5 | 8.4 - 12.5 | 10.72 | In |
Call | AKRO250321C00025000 | 212 | 25.0 | 7.5 - 12.0 | 9.77 | In |
Call | AKRO250321C00027500 | 2832 | 27.5 | 8.5 - 11.0 | 9.3 | Out |
Call | AKRO250321C00030000 | 547 | 30.0 | 6.3 - 10.5 | 9.4 | Out |
Call | AKRO250321C00032500 | 0 | 32.5 | 5.2 - 9.9 | 5.2 | |
Call | AKRO250321C00035000 | 0 | 35.0 | 4.1 - 8.9 | 4.1 | |
Call | AKRO250321C00037500 | 0 | 37.5 | 4.7 - 8.5 | 4.7 | |
Call | AKRO250321C00040000 | 34 | 40.0 | 4.4 - 8.0 | 4.68 | Out |
Put | AKRO250321P00015000 | 2 | 15.0 | 1.9 - 5.0 | 3.45 | Out |
Put | AKRO250321P00017500 | 0 | 17.5 | 2.5 - 6.5 | 2.5 | |
Put | AKRO250321P00020000 | 21 | 20.0 | 4.4 - 8.0 | 6.2 | Out |
Put | AKRO250321P00022500 | 3 | 22.5 | 6.3 - 10.0 | 6.6 | Out |
Put | AKRO250321P00025000 | 1 | 25.0 | 7.8 - 11.5 | 8.09 | Out |
Put | AKRO250321P00027500 | 0 | 27.5 | 9.0 - 13.5 | 9.0 | In |
Put | AKRO250321P00030000 | 4 | 30.0 | 10.5 - 15.0 | 12.37 | In |
Put | AKRO250321P00032500 | 0 | 32.5 | 12.5 - 17.0 | 12.5 | In |
Put | AKRO250321P00035000 | 18 | 35.0 | 14.5 - 18.5 | 12.25 | In |
Put | AKRO250321P00037500 | 0 | 37.5 | 16.5 - 20.5 | 16.5 | In |
Put | AKRO250321P00040000 | 0 | 40.0 | 18.1 - 22.5 | 18.1 | In |
Akero Therapeutics Market Cap Over Time
Market Cap |
| Timeline |
Akero Total Stockholder Equity
Total Stockholder Equity |
|
Akero Therapeutics Corporate Management
| Timothy Rolph | CoFounder Officer | Profile | |
| Patrick Lamy | Senior Strategy | Profile | |
| Scott Gangloff | Chief Officer | Profile | |
| Catriona Yale | Executive Officer | Profile | |
| William JD | CFO, VP | Profile | |
| David JD | Vice Legal | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Akero Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Akero Stock, please use our How to Invest in Akero Therapeutics guide.You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Akero Therapeutics. If investors know Akero will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Akero Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Akero Therapeutics is measured differently than its book value, which is the value of Akero that is recorded on the company's balance sheet. Investors also form their own opinion of Akero Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Akero Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Akero Therapeutics' market value can be influenced by many factors that don't directly affect Akero Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Akero Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Akero Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Akero Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.